Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: J Hepatol. 2011 Apr 14;55(6):1281–1290. doi: 10.1016/j.jhep.2011.03.017

The mice were injected intraperitoneally with the cPLA₂α inhibitor pyrrolidine (3 mg/kg body weight) or the EGFR inhibitor AG1478 (25 mg/kg body weight) 30 minutes before intraperitoneal administration of Jo2 (0.5 mg/kg body weight). The animals were sacrificed 4 hours after Jo2 injection and the liver tissues were harvested. (A) Representative H&E (a-c) and TUNEL stains (d-f) (200×) of the liver tissues from mice pretreated with or without inhibitors (all the mice received Jo2 injection). (B) Quantitation of TUNEL-positive hepatocytes in mice pretreated with or without inhibitors (*p < 0.01 compared to the corresponding cPLA₂α Tg mice without inhibitor pretreatment, n = 6). (C) Serum transaminases. Upon sacrifice the blood samples were collected for serum transaminase analysis. Pretreatment with inhibitors induced significantly higher serum ALT and AST levels when compared to pretreatment with vehicle control. *p<0.01 compared to the corresponding cPLA₂α Tg mice without inhibitor pretreatment (n = 6). (D) Caspase activities. The liver tissue homogenates were analyzed for caspase-3, 9, and 8 activities by fluorometric assay with Ac-DEVD-AFC, Ac-LEHD-AFC, and Ac-IETD-AFC as substrate, respectively. The data are expressed as mean ±SD of changes over wild type livers (n = 6 for each group). *p<0.01 compared to the corresponding cPLA₂α Tg mice without inhibitor pretreatment.

The mice were injected intraperitoneally with the cPLA₂α inhibitor pyrrolidine (3 mg/kg body weight) or the EGFR inhibitor AG1478 (25 mg/kg body weight) 30 minutes before intraperitoneal administration of Jo2 (0.5 mg/kg body weight). The animals were sacrificed 4 hours after Jo2 injection and the liver tissues were harvested. (A) Representative H&E (a-c) and TUNEL stains (d-f) (200×) of the liver tissues from mice pretreated with or without inhibitors (all the mice received Jo2 injection). (B) Quantitation of TUNEL-positive hepatocytes in mice pretreated with or without inhibitors (*p < 0.01 compared to the corresponding cPLA₂α Tg mice without inhibitor pretreatment, n = 6). (C) Serum transaminases. Upon sacrifice the blood samples were collected for serum transaminase analysis. Pretreatment with inhibitors induced significantly higher serum ALT and AST levels when compared to pretreatment with vehicle control. *p<0.01 compared to the corresponding cPLA₂α Tg mice without inhibitor pretreatment (n = 6). (D) Caspase activities. The liver tissue homogenates were analyzed for caspase-3, 9, and 8 activities by fluorometric assay with Ac-DEVD-AFC, Ac-LEHD-AFC, and Ac-IETD-AFC as substrate, respectively. The data are expressed as mean ±SD of changes over wild type livers (n = 6 for each group). *p<0.01 compared to the corresponding cPLA₂α Tg mice without inhibitor pretreatment.